Trial Profile
A retrospective study evaluating efficacy and safety of antiviral therapy (sofosbuvir + simeprevir or sofosbuvir + daclatasvir) for recurrent HCV in liver transplant recipients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Apr 2018
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Simeprevir (Primary) ; Sofosbuvir (Primary) ; Interferon; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 06 Apr 2018 New trial record
- 01 Mar 2018 Results published in the Transplantation Proceedings